Optimal Timing for Expanding Diagnostic Laboratories, South Korea.

Publication date: Aug 01, 2025

The rapid expansion of testing capacity is imperative for an adequate response to infectious diseases, such as COVID-19. South Korea rapidly secured large-scale testing during the early stages of COVID-19 in 2020 by leveraging the country’s experience with the 2015 Middle East respiratory syndrome outbreak; the initial response was relatively successful. A key difference between the 2 outbreak responses was the expansion from public to private testing laboratories during the COVID-19 pandemic. Expanding testing capacity during an infectious disease crisis should involve consideration of the overall response system and social conditions and not just the number of patients. If there are concerns about a crisis developing, testing capacity expansion should begin as soon as possible. Furthermore, accuracy should be ensured, especially when testing capacity is expanded. South Korea’s experience in developing diagnostic systems and adopting testing strategies underscores the value of proactive and well-timed preparedness for emerging infection disease outbreaks.

Open Access PDF

Concepts Keywords
Expanding communicable diseases
Korea coronavirus disease
Laboratories coronavirus infection
Pandemic COVID-19
Private COVID-19
COVID-19 Testing
diagnostic laboratories
Disease Outbreaks
Humans
infectious diseases
Laboratories
Laboratories, Clinical
MERS
Pandemics
Republic of Korea
respiratory infections
SARS
SARS-CoV-2
SARS-CoV-2
South Korea
Time Factors
viruses
zoonoses

Semantics

Type Source Name
disease MESH infectious diseases
disease MESH COVID-19
disease IDO country
disease MESH Middle East respiratory syndrome
pathway REACTOME Infectious disease
disease IDO infectious disease
disease MESH infection
disease MESH Emergency
disease IDO reagent
disease MESH tic
disease MESH virus infections
disease MESH Emerging Infectious Diseases
disease MESH hospital infection
disease IDO symptom
drug DRUGBANK Coenzyme M
disease IDO process
drug DRUGBANK Aspartame
drug DRUGBANK Trestolone
disease MESH anxiety
disease MESH confusion
disease MESH uncertainty
disease IDO pathogen
disease MESH monkeypox
disease IDO production
disease IDO quality
pathway KEGG Coronavirus disease
disease MESH respiratory infections
disease MESH zoonoses

Original Article

(Visited 2 times, 1 visits today)